OCUL News
Archived Headlines
- July biotech blitz and the upcoming eye, ear and nose IPOs 07/22/14
- Eye disease biotech Avalanche Biotechnologies sets terms for $76 million IPO 07/21/14
- 14 US IPOs planned for the week of Jul 21 07/21/14
- Late-stage eye disease biotech Ocular Therapeutix sets terms for $75 million IPO 07/11/14
- Sustained-release eye pharmaceutical Ocular Therapeutix files for a $86 million IPO 06/20/14
Year's fourth eye-focused biotech EyeGate Pharmaceuticals sets terms for $25 million IPO
EyeGate Pharmaceuticals, a late-stage biotech developing a treatment for eye inflammation, announced terms for its IPO on Friday. The Waltham, MA-based company plans to raise $25 million by offering 2.0 million shares at a price range of $12 to $14. Insiders...read more
Biotech EyeGate Pharmaceuticals files for a $29 million IPO
EyeGate Pharmaceuticals, a late-stage biotech developing a therapy for eye inflammation, filed on Wednesday with the SEC to raise up to $29 million in an initial public offering. The company has completed a Phase 3 trial for its combined inflammation...read more
US IPO Pricing Recap: The crazy chicken flies while 8 IPOs trade down or flat
This week's 10 IPOs largely disappointed as 70% were forced to price below the proposed range and 80% closed the week up 1% or less. Before this week, only 36% of IPOs this year had first-day pops of 1% or less. The enthusiasm for last week's ...read more
Ocular Therapeutix prices IPO below the range at $13
Ocular Therapeutix, which develops eye therapies using a sustained-release hydrogel platform, raised $65 million by offering 5 million shares at $13, below the range of $14 to $16. Ocular Therapeutix plans to list on the NASDAQ under the symbol OCUL. Ocular...read more